Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4726
Source ID: NCT03670043
Associated Drug: Psyllium Powder
Title: Tolerance & Responsiveness Improvement for Metformin (TRIM)
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type2 Diabetes Mellitus
Interventions: DRUG: Psyllium powder|DRUG: Metformin Extended Release Oral Tablet
Outcome Measures: Primary: Birmingham Irritable Bowel Syndrome (IBS) Symptom Questionnaire, This scale is based on symptoms that frequently occur in IBS cases, examines abdominal discomfort status, stool properties, and defecation feelings. The scale includes a total of 11 items, with 6 possible grades for each item that range from 0 points (never having this symptom) to 5 points (the symptom is always present). The total score is the sum of the scores for each item. The Total score is used. No "subscale" is used. Total range is minimum=0, maximum=55. The higher values represent a worse outcome., 3 months |
Sponsor/Collaborators: Sponsor: West Side Institute for Science and Education
Gender: MALE
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 29
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2019-03-19
Completion Date: 2021-08-15
Results First Posted:
Last Update Posted: 2021-09-10
Locations: Jesse Brown VA Medical Center, Chicago, Illinois, 60612, United States
URL: https://clinicaltrials.gov/show/NCT03670043